Clinitech Laboratory Ltd
Incorporated in 1990, Clinitech Laboratory Ltd is in the business of providing pathology and related healthcare services.[1]
- Market Cap ₹ 9.13 Cr.
- Current Price ₹ 40.0
- High / Low ₹ 57.0 / 28.6
- Stock P/E 21.7
- Book Value ₹ 40.5
- Dividend Yield 0.00 %
- ROCE 7.20 %
- ROE 4.65 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.99 times its book value
- Promoter holding has increased by 1.78% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 8.23 | 9.49 | |
| 7.40 | 8.50 | |
| Operating Profit | 0.83 | 0.99 |
| OPM % | 10.09% | 10.43% |
| 0.23 | 0.19 | |
| Interest | 0.06 | 0.07 |
| Depreciation | 0.45 | 0.51 |
| Profit before tax | 0.55 | 0.60 |
| Tax % | 29.09% | 30.00% |
| 0.39 | 0.42 | |
| EPS in Rs | 1.71 | 1.84 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 2.28 | 2.28 |
| Reserves | 6.55 | 6.97 |
| 0.00 | 0.54 | |
| 2.01 | 1.39 | |
| Total Liabilities | 10.84 | 11.18 |
| 3.13 | 3.17 | |
| CWIP | 0.00 | 0.26 |
| Investments | 0.07 | 0.07 |
| 7.64 | 7.68 | |
| Total Assets | 10.84 | 11.18 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -0.88 | -0.79 | |
| -0.73 | -0.68 | |
| 3.98 | 0.51 | |
| Net Cash Flow | 2.37 | -0.96 |
| Free Cash Flow | -1.73 | -1.60 |
| CFO/OP | -87% | -59% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 68.30 | 71.15 |
| Inventory Days | 124.01 | 117.90 |
| Days Payable | 177.82 | 77.52 |
| Cash Conversion Cycle | 14.48 | 111.53 |
| Working Capital Days | 114.87 | 158.85 |
| ROCE % | 7.20% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Intangible Assets Under Development INR Lakhs ・Standalone data |
|
|
| Plant and Machinery (Gross Block) INR Lakhs ・Standalone data |
||
| IPO Funds Utilized for Diagnostic Business Expansion INR Lakhs ・Standalone data |
||
| Multi-specialty Hospital Tie-ups Added count ・Standalone data |
||
| New Service Centers Opened (Branches + Collection Centers) count ・Standalone data |
||
| Permanent Employees count ・Standalone data |
||
| Revenue per Employee INR Lakhs per employee ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jul - Regulation 74(5) disclosure for quarter ended June 30, 2026; no rematerialisation requests received.
-
Statement Of Deviation & Variation As On March 31, 2026
28 May - Filed March 31, 2026 IPO fund utilization statement for ₹578.30 lakh; no deviation or variation reported.
- Results- Financial Results For Half Year And Financial Year Ended March 31, 2026 28 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held For FY 2026-27 Today I.E May 28, 2026 Through Video Conferencing At 02.30 P.M
28 May - Board approved audited standalone and consolidated FY2026 results on May 28, 2026; auditors issued unmodified opinion.
-
Board Meeting Intimation for Board Meeting For FY 2026-27 To Be Held On Thrusday, May 28, 2026 At 02.30 P.M Through Video Conferencing
22 May - Board meets May 28, 2026 to approve audited FY26 financial results and note internal audit.
Business Overview:[1]
CTLL in the business of providing NABL
accredited healthcare services such as:
a) Pathology testing labs
b) Diagnostic centres
c) Scan centres
d) X-ray centres
e) ECG clinics